Wyeth and Solvay end collaboration agreements

Collaboration agreements between Wyeth Pharmaceuticals and Solvay Pharmaceuticals have come to an end.

The two companies worked together on the development and commercialisation of various compounds aimed at the potential treatment of schizophrenia and other psychiatric disorders.

One of the drugs included in the collaboration was investigational atypical antipsychotic bifeprunox.

However, Wyeth Pharmaceuticals – a division of Wyeth – said that after assessment of bifeprunox, there was not enough commercial value to be shared between it and Solvay.

All North American global commercialisation and development rights for the drug will now revert to Solvay, it was concluded.

Meanwhile, Wyeth currently has a range of products in its pipeline at Phase III, including Lybrel (levonorgestrel/EE) for premenstrual dysphoric disorder and Aprela (bazedoxifine/conjugated estrogens) for the treatment of postmenopausal osteoporosis.